Boosh Announces the Closing of its Private Placement Offering and Opens Listing Issuer Exemption Offering

Boosh Announces the Closing of its Private Placement Offering and Opens Listing Issuer Exemption Offering

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector, is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement financing. In total, the Company has raised $362,000.00 CAD via the sale of 7,240,000 Units. Each Unit is comprised of one Common Share of the Company and one Purchase Warrant, with each Warrant exercisable into one Common Share of the Company at a price of $0.07 CAD at any time on or before the date which is 12 months from the closing of the offering. In connection with the offering, the Company paid $1,750.00 CAD in finders fees. Proceeds from the Offering will be used for general working capital purposes and to further advance the Company's business.

Boosh is pleased to announce it plans to raise an additional $400,000 in the form of a Listed Issuer Exemption at .05 per common share with an additional .07 one purchase warrant, with each Warrant exercisable into one Common Share of the Company at a price of $0.07 CAD at any time on or before the date which is 12 months from the closing of the offering. Equity securities issued in reliance on the exemption will be freely tradeable.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The Corporation also announced today that it had issued 750,000 Stock Options to employees and consultants to the Company. No Management or Directors of the Company were recipients to the Stock Options. All Stock Options issued vest immediately and are exercisable at a price of $0.05 CAD per Stock Option. The Stock Options expire 1 year after the date of issuance. The Company further announced that it had also settled a combined total of $328,124.98 CAD in debt owed to several creditors via the issuance of 11,979,166 Common Shares. The debt settlement has vastly improved the Company's balance sheet.

Connie Marples
Founder/CEO
connie@booshfood.com
Telephone: 778 840 1700
www.Booshfood.com

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com) offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. Through a separate subsidiary, Beautiful Beanfields, (www.beanfields.com) the Company owns Beanfields, a plant-based chip brand sold in over 7,000 stores throughout North America. Boosh, good for you and good for planet earth.

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward- looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CSE nor its Regulation Services Provider as that term is defined in the policies of the CSE accepts responsibility for the adequacy or accuracy of this release. We seek safe harbor.

- 30 -

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/158395

News Provided by Newsfile via QuoteMedia

VEGI:CC
The Conversation (0)
Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, announced today it is working with Pixie Brands @meetpixiebrands and Multi Brand Sampling Co @multibrandsmaplingco to promote and enhance sales at store level for all Boosh and Beanfields brands in BC.

Founded by CPG founder April Angelini, Pixie Brands offers a relationship-based, boots on the ground approach to help small and medium brands SHINE. They offer sales and distributor support and organize In-Store Events.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Boosh Expands into United Sates Hospitality Services Sector

Boosh Expands into United Sates Hospitality Services Sector

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector announced today it has begun production of 1.5 oz bags of Beanfields Chips to open up sales to the US hospitality sector. Beanfields Snacks, the primary asset of Boosh Plant Based Brands, represents a significant growth opportunity in the salty snacks sector.

Prior to Boosh Plant-Based Brands acquiring the asset Beanfields Chips, the previous owners had made inroads into the hospitality sector with accounts at Universities, Corporate offices and numerous independent quick serve and convenience stores representing annual sales of $1.7M CAN.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Boosh Announces Shares for Debt Transaction

Boosh Announces Shares for Debt Transaction

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector announced today that it had entered into, and that it had finalized a secondary set of debt settlement agreements with the purpose to both satisfy and to extinguish an aggregate total of C$722,710 of secured debts. A combined total of 16,060,207 common shares were issued at a deemed price of C$0.045 per common share.

The Company decided to satisfy the indebtedness with common shares to preserve its cash for the development of its business. No new control person of the Company will be created pursuant to the settlement of the debt settlement agreements.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Boosh Plant-Based Brands Inc. Announces Engagement with Storied Health Partners and Debt Settlement

Boosh Plant-Based Brands Inc. Announces Engagement with Storied Health Partners and Debt Settlement

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, is pleased to announce that it has engaged Storied Health Partners, a resource-rich platform that provides entrepreneurs the support and leverage they need to maximize their growth potential and accomplish their brand's next milestone.

CEO of Storied Health Partners, Anis Barakat, is a food and beverage expert with nearly a decade of experience in senior leadership roles in the industry. Mr. Barakat is the founder and former President of Revive Superfoods, the first multi-national frozen superfood subscription company selling ready-to-eat/blend meals such as smoothies, oats, soups and lunch/dinner bowls direct-to-consumer throughout the United States, Canada and UAE. During his time with Revive Superfoods, Anis was instrumental in developing a highly scalable direct-to-consumer ("DTC") subscription model that disrupted the ready-meal industry and achieved incredible success since its inception in 2018.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
CORRECTION FROM SOURCE: Correction of the Press Releases Dated January 9, 2023 and March 14, 2023

CORRECTION FROM SOURCE: Correction of the Press Releases Dated January 9, 2023 and March 14, 2023

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, issues the following corrected press release to the press releases dated January 9, 2023 and March 14, 2023 concerning the completion of a non-brokered private placement for gross proceeds of $362,000.

The corrections are being made to correct and restate the terms of the previously announced non-brokered private placement.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation
maintained throughout the 26-week study

Episodes of pericarditis per year substantially reduced

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×